Company / Shareholders' Equity
Maze Therapeutics, Inc. Shareholders' Equity History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$355.0M
FY2025
5-year range
$355.0M / $355.0M
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#115 of 213
Health Care
What the data says
At $355M, Maze Therapeutics, Inc.'s shareholders' equity ranks #115 of 213 in the Health Care sector.
Based on SEC 10-K filings.
$355M in FY2025.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#115 of 213 in Health CareTop 54% of 213This company $355.0M Sector average $2.5B
▼
-86.1% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $355.0M | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026